Neda Rajaeean
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Neda Rajaeean has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Christian Lenz
Pfizer Pharma GmbH, Berlin, Germany
1 shared publication- Dina Domrös-Zoungrana
Pfizer Pharma GmbH, Berlin, Germany
1 shared publication - Emma Fröling
Pfizer Pharma GmbH, Berlin, Germany
1 shared publication - Johannes Nico Urban
Pfizer Pharma GmbH, Berlin, Germany
1 shared publication - Klara Sonnie Hinrichsmeyer
Pfizer Pharma GmbH, Berlin, Germany
1 shared publication
Latest Publications
- Open Access
- 11 September 2024
- Published by Springer Nature in Pharmaceutical Medicine
- Vol. 38 (5) , 331-342
Artificial Intelligence in Medical Affairs: A New Paradigm with Novel Opportunities
The advent of artificial intelligence (AI) revolutionizes the ways of working in many areas of business and life science. In Medical Affairs (MA) departments of the pharmaceutical industry AI holds great potential for positively influencing the medical mission of identifying and addressing unmet medical needs and care gaps, and fostering solutions that improve the egalitarian and unbiased access of patients to treatments worldwide. Given the essential position of MA in corporate interactions with various healthcare stakeholders, AI offers broad possibilities to support strategic decision-making and to pioneer novel approaches in medical stakeholder interactions. By analyzing data derived from the healthcare environment and by streamlining operations in medical content generation, AI advances data-based prioritization and strategy execution. In this review, we discuss promising AI-based solutions in MA that support the effective use of heterogenous information from observations of the healthcare environment, the enhancement of medical education, and the analysis of real-world data. For a successful implementation of such solutions, specific considerations partly unique to healthcare must be taken care of, for example, transparency, data privacy, healthcare regulations, and in predictive applications, explainability.
- 11 September 2024
- Published by Springer Nature in Pharmaceutical Medicine
- Vol. 38 (5) , 331-342
Open AccessArtificial Intelligence in Medical Affairs: A New Paradigm with Novel Opportunities
The advent of artificial intelligence (AI) revolutionizes the ways of working in many areas of business and life science. In Medical Affairs (MA) departments of the pharmaceutical industry AI holds great potential for positively influencing the medical mission of identifying and addressing unmet medical needs and care gaps, and fostering solutions that improve the egalitarian and unbiased access of patients to treatments worldwide. Given the essential position of MA in corporate interactions with various healthcare stakeholders, AI offers broad possibilities to support strategic decision-making and to pioneer novel approaches in medical stakeholder interactions. By analyzing data derived from the healthcare environment and by streamlining operations in medical content generation, AI advances data-based prioritization and strategy execution. In this review, we discuss promising AI-based solutions in MA that support the effective use of heterogenous information from observations of the healthcare environment, the enhancement of medical education, and the analysis of real-world data. For a successful implementation of such solutions, specific considerations partly unique to healthcare must be taken care of, for example, transparency, data privacy, healthcare regulations, and in predictive applications, explainability.